

FORWARD thinning/thickening manuscript_re-submission_December 2019

Supplementary Table S3 Change from baseline in cartilage thickness (μm) by sub-region at 24 months (mITT Analysis Set)

Sub-region	Placebo	Sprifermin 100 μg q6mo
Mean (95% CI)	(N=96)	(N=101)
Central MT	-67.5 (-113.2, -21.8)	17.7 (-14.2, 49.7)
External MT	-43.4 (-79.0, -7.8)	4.7 (-16.1, 25.5)
Internal MT	-18.3 (-47.2, 10.5)	4.4 (-13.3, 22.2)
Anterior MT	-11.2 (-33.0, 10.6)	25.7 (9.1, 42.3)
Posterior MT	2.2 (-16.6, 21.1)	18.0 (1.1, 35.0)
Central cMF	-43.6 (-79.0, -8.2)	36.4 (2.7, 70.1)
External cMF	-37.1 (-70.2, -4.0)	36.9 (13.2, 60.6)
Internal cMF	-23.3 (-51.2, 4.5)	8.5 (-18.2, 35.2)
Central LT	-29.1 (-51.3, -6.8)	22.6 (-4.6, 49.8)
External LT	-2.3 (-14.9, 10.2)	23.1 (7.4, 38.9)
Internal LT	-24.2 (-39.7, -8.6)	2.8 (-11.6, 17.3)
Anterior LT	-1.1 (-22.5, 20.4)	15.3 (-0.4, 31.0)
Posterior LT	-2.7 (-22.1, 16.7)	6.8 (-11.4, 25.1)
Central cLF	-19.2 (-44.8, 6.4)	90.0 (60.4, 119.6)
External CLF	-3.8 (-19.3, 11.8)	75.1 (54.3, 95.9)
Internal cLF	-10.4 (-25.7, 5.0)	35.9 (15.9, 55.9)

CI, confidence interval; cLF, central lateral femoral condyle; cMF, central medial femoral condyle; LT, lateral tibia; mITT, modified intention-to-treat; MT, medial tibia; q6mo, every 6 months active cycle.